Journal List > J Korean Diabetes > v.17(1) > 1055045

Yoon, Kim, Bae, Yun, Lee, Lee, Ahn, Cha, Lee, and Kang: A Case of Autoantibody-Positive Ketosis-Prone Diabetes Mellitus

Abstract

Ketosis-prone diabetes mellitus (KPD), which is an atypical type of diabetic mellitus with severe β cell dysfunction, is accompanied by ketosis or ketoacidosis without specific preceding factors at diagnosis. KPD shows mixed features of type 1 and type 2 diabetes. In some cases, the recovery of the function of β cells during intensified diabetic management enabled the termination of insulin therapy. The Aβ classification system classifies KPD patients into four distinct subgroups depending upon the presence or absence of β cell autoimmunity and β cell functional reserve and has been recognized as an important tool to predict clinical outcomes. In Korea, several cases of KPD with absence of β cell autoimmunity have been reported. A 60-year-old man presenting with DKA (diabetic ketoacidosis) as the first manifestation of diabetes, was shown to have β cell autoimmunity. A significant improvement in glycemic control was shown as a result of aggressive diabetic management; shortly after an acute episode of DKA, the recovery of β cell functional reserve was confirmed. This result allowed discontinuation of insulin therapy and maintenance of euglycemic status without antidiabetic medication.

References

1. Maldonado M, Hampe CS, Gaur LK, D'Amico S, Iyer D, Hammerle LP, Bolgiano D, Rodriguez L, Rajan A, Lernmark A, Balasubramanyam A. Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis, and clinical outcomes. J Clin Endocrinol Metab. 2003; 88:5090–8.
2. Winter WE, Maclaren NK, Riley WJ, Clarke DW, Kappy MS, Spillar RP. Maturity-onset diabetes of youth in black Americans. N Engl J Med. 1987; 316:285–91.
crossref
3. Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes mellitus. Endocr Rev. 2008; 29:292–302.
crossref
4. Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med. 2006; 144:350–7.
crossref
5. Kim DL, Kim SK, Song KH. A case of ketosis-prone type 2 diabetes mellitus. J Korean Diabetes Assoc. 2007; 31:293–6.
crossref
6. Lee CW, Ryu MS, Lee MY, Lee MJ, Choi JS, Kang JG, Kim CS, Lee SJ, Hong EG, Kim DM, Yu SH, Ihm SH, Yu JM, Choi MG, Yoo HJ, Ryu OH. Four cases of ketosis-prone diabetes mellitus. Korean Clinical Diabetes J. 2011; 10:342–8.
crossref
7. Umpierrez GE, Woo W, Hagopian WA, Isaacs SD, Palmer JP, Gaur LK, Nepom GT, Clark WS, Mixon PS, Kitabchi AE. Immunogenetic analysis suggests different pathogenesis for obese and lean African-Americans with diabetic ketoacidosis. Diabetes Care. 1999; 22:1517–23.
crossref
8. Mauvais-Jarvis F, Sobngwi E, Porcher R, Riveline JP, Kevorkian JP, Vaisse C, Charpentier G, Guillausseau PJ, Vexiau P, Gautier JF. Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance. Diabetes. 2004; 53:645–53.
9. Balasubramanyam A, Zern JW, Hyman DJ, Pavlik V. New profiles of diabetic ketoacidosis: type 1 vs type 2 diabetes and the effect of ethnicity. Arch Intern Med. 1999; 159:2317–22.
10. Umpierrez GE, Casals MM, Gebhart SP, Mixon PS, Clark WS, Phillips LS. Diabetic ketoacidosis in obese African-Americans. Diabetes. 1995; 44:790–5.
crossref
11. Balasubramanyam A, Garza G, Rodriguez L, Hampe CS, Gaur L, Lernmark A, Maldonado MR. Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care. 2006; 29:2575–9.
crossref
12. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulindependent onset of disease. Diabetes. 1993; 42:359–62.
crossref
13. Reed Larsen P, Kronenberg HM, Melmed S, Polonsky KS. Williams textbook of endocrinology. 10th ed.Philadelphia: W.B. Saunders Company;2003. p1443.
14. Newton CA, Raskin P. Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences. Arch Intern Med. 2004; 164:1925–31.
15. Mauvais-Jarvis F, Smith SB, Le May C, Leal SM, Gautier JF, Molokhia M, Riveline JP, Rajan AS, Kevorkian JP, Zhang S, Vexiau P, German MS, Vaisse C. PAX4 gene variations predispose to ketosis-prone diabetes. Hum Mol Genet. 2004; 13:3151–9.
crossref
16. Hampe CS, Nalini R, Maldonado MR, Hall TR, Garza G, Iyer D, Balasubramanyam A. Association of aminoterminal-specific antiglutamate decarboxylase (GAD65) autoantibodies with beta-cell functional reserve and a milder clinical phenotype in patients with GAD65 antibodies and ketosis-prone diabetes mellitus. J Clin Endocrinol Metab. 2007; 92:462–7.

Table 1.
Baseline clinical characteristics of subjec cts (n = 45)
Variable On admission On discharge (45 days after admission)
Random plasma glucose (mg/dL) 1440 156
C-peptide (ng/mL) 0.58  
HbA1C (%) 16.1 7.0
Glycoalbumin (%) 65 18.0
GAD antibody (U/mL) 53.08 28.16
Islet cell antibody   Negative
Serum osmolarity (mOsm/kg) 437  
Urine osmolarity (mOsm/kg) 445  
Urine ketone 1+  
Serum Na (mmol/L) 145 144
Serum K (mmol/L) 2.4 3.7
Serum Cl (mmol/L) 109 116
ABGAa
pH 7.213  
pCO2 (mm Hg) 21.4  
pO2 (mm Hg) 318.3  
(mmol/L) HCO3 8.7  
3 Base excess (mmol/L) –19.3  
BUN (mg/dL) 82.7 8.6
Cr (mg/dL) 7.53 1.43
Fasting plasma glucose (mg/dL)   96
2-hour postprandial plasma glucose (mg/dL)   135
Fasting C-peptide (ng/mL)   2.12
2-hour postprandial C-peptide (ng/mL)   3.89
Fasting insulin (μU/mL)   4.34
2-hour postprandial insulin (μU/mL)   11.66

GAD, glutamic acid decarboxylase; BUN, blood urea nitrogen; Cr, creatinine.

a FiO 40%.

TOOLS
Similar articles